EP1638569A1 - Use of brimonidine for preventing and reducing the severity of stress-associated conditions - Google Patents
Use of brimonidine for preventing and reducing the severity of stress-associated conditionsInfo
- Publication number
- EP1638569A1 EP1638569A1 EP04755981A EP04755981A EP1638569A1 EP 1638569 A1 EP1638569 A1 EP 1638569A1 EP 04755981 A EP04755981 A EP 04755981A EP 04755981 A EP04755981 A EP 04755981A EP 1638569 A1 EP1638569 A1 EP 1638569A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- condition
- disorder
- brimonidine
- severity
- muscle contraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 title claims abstract description 86
- 229960003679 brimonidine Drugs 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 111
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 150000001408 amides Chemical class 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 150000002148 esters Chemical class 0.000 claims abstract description 17
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 13
- 206010020751 Hypersensitivity Diseases 0.000 claims description 87
- 208000026935 allergic disease Diseases 0.000 claims description 84
- 230000009610 hypersensitivity Effects 0.000 claims description 82
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 50
- 208000035475 disorder Diseases 0.000 claims description 46
- 208000001871 Tachycardia Diseases 0.000 claims description 32
- 230000006794 tachycardia Effects 0.000 claims description 32
- 230000001953 sensory effect Effects 0.000 claims description 26
- 230000004118 muscle contraction Effects 0.000 claims description 25
- 201000006549 dyspepsia Diseases 0.000 claims description 24
- 208000019695 Migraine disease Diseases 0.000 claims description 19
- 201000003146 cystitis Diseases 0.000 claims description 19
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 18
- 206010027599 migraine Diseases 0.000 claims description 18
- 208000019906 panic disease Diseases 0.000 claims description 17
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 15
- 206010033664 Panic attack Diseases 0.000 claims description 13
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 11
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 11
- 230000003542 behavioural effect Effects 0.000 claims description 10
- 206010069918 Bacterial prostatitis Diseases 0.000 claims description 9
- 208000010643 digestive system disease Diseases 0.000 claims description 8
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 8
- 208000031225 myocardial ischemia Diseases 0.000 claims description 8
- 206010022489 Insulin Resistance Diseases 0.000 claims description 7
- 230000016160 smooth muscle contraction Effects 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 230000012232 skeletal muscle contraction Effects 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 abstract description 20
- 230000009467 reduction Effects 0.000 abstract description 11
- 238000011813 knockout mouse model Methods 0.000 description 56
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 49
- 229960002896 clonidine Drugs 0.000 description 49
- 102000005962 receptors Human genes 0.000 description 41
- 108020003175 receptors Proteins 0.000 description 41
- UQZVCDCIMBLVNR-TWYODKAFSA-N sulprostone Chemical compound O[C@@H]1CC(=O)[C@H](C\C=C/CCCC(=O)NS(=O)(=O)C)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 UQZVCDCIMBLVNR-TWYODKAFSA-N 0.000 description 37
- 229960003400 sulprostone Drugs 0.000 description 37
- 230000035882 stress Effects 0.000 description 36
- 239000000556 agonist Substances 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 34
- 230000000694 effects Effects 0.000 description 28
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 27
- 229960001802 phenylephrine Drugs 0.000 description 27
- 235000002639 sodium chloride Nutrition 0.000 description 24
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 230000004044 response Effects 0.000 description 19
- 206010039897 Sedation Diseases 0.000 description 18
- 230000036280 sedation Effects 0.000 description 18
- 230000002889 sympathetic effect Effects 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 17
- 206010070834 Sensitisation Diseases 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 230000008313 sensitization Effects 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 239000003981 vehicle Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 230000000202 analgesic effect Effects 0.000 description 14
- 238000007912 intraperitoneal administration Methods 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 14
- 229960000488 tizanidine Drugs 0.000 description 14
- 230000035945 sensitivity Effects 0.000 description 13
- 231100000673 dose–response relationship Toxicity 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 210000002820 sympathetic nervous system Anatomy 0.000 description 11
- 206010019233 Headaches Diseases 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 10
- 229960003602 guanethidine Drugs 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 231100000869 headache Toxicity 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000007913 intrathecal administration Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 201000004624 Dermatitis Diseases 0.000 description 8
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 8
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 7
- 208000001640 Fibromyalgia Diseases 0.000 description 7
- 206010028813 Nausea Diseases 0.000 description 7
- 208000005392 Spasm Diseases 0.000 description 7
- 238000000692 Student's t-test Methods 0.000 description 7
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 7
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 7
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 230000008693 nausea Effects 0.000 description 7
- 229960002748 norepinephrine Drugs 0.000 description 7
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- HIHZDNKKIUQQSC-UHFFFAOYSA-N 6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propylamino]-1,3,5-trimethylpyrimidine-2,4-dione Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2C)C)CC1 HIHZDNKKIUQQSC-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- -1 dihydrochloride Chemical compound 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 6
- 229960001289 prazosin Drugs 0.000 description 6
- 238000012353 t test Methods 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 238000002825 functional assay Methods 0.000 description 5
- 208000021803 junctional tachycardia Diseases 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 201000007094 prostatitis Diseases 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 5
- 208000017520 skin disease Diseases 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- IRAOSCSPAYZRJE-UHFFFAOYSA-N 5-bromoquinoxalin-6-amine Chemical compound N1=CC=NC2=C(Br)C(N)=CC=C21 IRAOSCSPAYZRJE-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 4
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 208000000060 Migraine with aura Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000000048 adrenergic agonist Substances 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 230000001746 atrial effect Effects 0.000 description 4
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 description 4
- 229960004253 dexmedetomidine Drugs 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000013265 extended release Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229960004640 memantine Drugs 0.000 description 4
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 4
- 230000037023 motor activity Effects 0.000 description 4
- 208000035824 paresthesia Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229950010131 puromycin Drugs 0.000 description 4
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 108060003345 Adrenergic Receptor Proteins 0.000 description 3
- 102000017910 Adrenergic receptor Human genes 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 description 3
- 206010048768 Dermatosis Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010034960 Photophobia Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 206010000059 abdominal discomfort Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 206010003668 atrial tachycardia Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001593 cAMP accumulation Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960002870 gabapentin Drugs 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000006742 locomotor activity Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 208000017972 multifocal atrial tachycardia Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000020911 optic nerve disease Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 230000009278 visceral effect Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- YKGMGCYABGHZRB-UHFFFAOYSA-N 5-bromoquinoxalin-6-amine;hydrobromide Chemical compound Br.N1=CC=NC2=C(Br)C(N)=CC=C21 YKGMGCYABGHZRB-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 208000006561 Cluster Headache Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 201000009053 Neurodermatitis Diseases 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010054956 Phonophobia Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010036313 Post-traumatic headache Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 201000007527 Retinal artery occlusion Diseases 0.000 description 2
- 206010057430 Retinal injury Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010057040 Temperature intolerance Diseases 0.000 description 2
- 208000028911 Temporomandibular Joint disease Diseases 0.000 description 2
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 description 2
- 206010043269 Tension headache Diseases 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 2
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 2
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 2
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000020830 overeating Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 230000009155 sensory pathway Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 206010047302 ventricular tachycardia Diseases 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- VOQPQBGCWBEYEV-AWEZNQCLSA-N (S)-1-(4-bromoacetamidobenzyl)EDTA Chemical compound OC(=O)CN(CC(O)=O)C[C@@H](N(CC(O)=O)CC(O)=O)CC1=CC=C(NC(=O)CBr)C=C1 VOQPQBGCWBEYEV-AWEZNQCLSA-N 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 description 1
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- CRNMXQMOFAYYEX-UHFFFAOYSA-N 5-bromo-6-isothiocyanatoquinoxaline Chemical compound C1=CN=C2C(Br)=C(N=C=S)C=CC2=N1 CRNMXQMOFAYYEX-UHFFFAOYSA-N 0.000 description 1
- DGBBBEKLSZQFSV-UHFFFAOYSA-N 6-bromo-6-isothiocyanato-5h-quinoxaline Chemical compound C1=CN=C2C=CC(Br)(N=C=S)CC2=N1 DGBBBEKLSZQFSV-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010049714 Abdominal migraine Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010051394 Allergic cystitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010069571 Atrioventricular dissociation Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010064888 Cervicogenic headache Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010048837 Cystitis glandularis Diseases 0.000 description 1
- 206010063057 Cystitis noninfective Diseases 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000032538 Depersonalisation Diseases 0.000 description 1
- 206010012422 Derealisation Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 102000043859 Dynamin Human genes 0.000 description 1
- 108700021058 Dynamin Proteins 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010059186 Early satiety Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010056246 Eosinophilic cystitis Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000010541 Familial or sporadic hemiplegic migraine Diseases 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000010271 Heart Block Diseases 0.000 description 1
- 206010019476 Hemiplegic migraine Diseases 0.000 description 1
- 101000756842 Homo sapiens Alpha-2A adrenergic receptor Proteins 0.000 description 1
- 101000720032 Homo sapiens Alpha-2C adrenergic receptor Proteins 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010066295 Keratosis pilaris Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010052784 Retinal migraine Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010041955 Stasis dermatitis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000001944 accentuation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000005661 acute cystitis Diseases 0.000 description 1
- 239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001908 autoinhibitory effect Effects 0.000 description 1
- OISFUZRUIGGTSD-LJTMIZJLSA-N azane;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound N.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000001841 basilar artery Anatomy 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000005845 branch retinal artery occlusion Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 229960001724 brimonidine tartrate Drugs 0.000 description 1
- QZHBYNSSDLTCRG-WUUYCOTASA-N brimonidine tartrate Chemical compound [H+].[H+].[O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O.C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 QZHBYNSSDLTCRG-WUUYCOTASA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 206010006514 bruxism Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000005849 central retinal artery occlusion Diseases 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 201000003139 chronic cystitis Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 206010067039 familial hemiplegic migraine Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 208000020390 granulomatous prostatitis Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000004886 head movement Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 102000046858 human ADRA2A Human genes 0.000 description 1
- 102000049999 human ADRA2C Human genes 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000010978 jasper Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 206010052787 migraine without aura Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000036225 muscular coordination Effects 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 208000017445 musculoskeletal system disease Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002746 orthostatic effect Effects 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 208000008510 paroxysmal tachycardia Diseases 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000001696 pelvic girdle Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 210000004044 posterior horn cell Anatomy 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000002522 prostaglandin receptor stimulating agent Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 230000001007 puffing effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- MSGRFBKVMUKEGZ-UHFFFAOYSA-N quinoxalin-6-amine Chemical compound N1=CC=NC2=CC(N)=CC=C21 MSGRFBKVMUKEGZ-UHFFFAOYSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- the invention relates generally to the sympathetic nervous system and various stress- associated conditions and, in particular, to the -2 adrenergic agonist, brimonidine.
- BACKGROUND INFORMATION Conditions that are associated with or exacerbated by stress can be mediated, at least in part, by the sympathetic nervous system.
- stress-associated conditions include, without limitation, gastrointestinal disease; irritable bowel syndrome; dyspepsia; tachycardia; panic attack; insulin-resistance; type II diabetes; dermatogical conditions; disorders of muscle contraction such as tension type headache; sensory hypersensitivity associated with migraine such as nausea, photophobia and phonophobia; and stress-associated behavioral disorders such as overeating and drug dependence.
- the present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective - amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof, where the stress-associated condition is one of the following: gastrointestinal disease; irritable bowel syndrome; dyspepsia; tachycardia; panic attack; insulin-resistance; type II diabetes; a noninflammatory dermatogical condition; a disorder of muscle contraction; sensory hypersensitivity associated with migraine; or .a stress-associated behavioral disorder.
- a method of the invention prevents or reduces the severity of gastrointestinal disease. In other embodiments, a method of the invention prevents or reduces the severity of irritable bowel, syndrome or dyspepsia. In another embodiment, a- method of the invention prevents or reduces the severity of tachycardia other than tachycardia associated with myocardial ischemia/ for example, tachycardia associated with a pulmonary disorder. In a further embodiment, a method of the invention prevents or reduces the severity of panic attack. In still further embodiments, a method* of the invention prevents or reduces the severity of insulin-resistance, or prevents or reduces the severity of type II diabetes.
- a method of the invention prevents or reduces the severity of a non-inflammatory dermatological condition.
- a method- of the invention prevents or reduces the severity of a disorder of muscle contraction such as a disorder of skeletal muscle contraction or a disorder of smooth muscle contraction, for example, a disorder of smooth muscle contraction associated with cystitis or associated with non-bacterial prostatitis or a disorder of muscle contraction associated with tension type headache.
- a method of the invention prevents or reduces the severity of sensory hypersensitivity associated with migraine.
- a method of the invention prevents or reduces the severity of sensory hypersensitivity associated with a stress-associated behavioral disorder.
- an effective amount of brimonidine can be administered by any of a variety of methods including, but not limited to, orally, topically, intravenously or via a patch.
- Figure 1 shows the tactile hypersensitivity observed with several, distinct chemical models.
- Each experimental group included 5-6 wildtype mice. Tactile hypersensitivity was assessed as described below; sensitization scores determined every 5 minutes during the 35 minute measurement period were summed and calculated as the mean +/- SEM. Each group was compared to a vehicle control using an unpaired two-tailed t-test (* p ⁇ .01, ** p ⁇ .001).
- the ⁇ -1 antagonist, 5-MU (30 ug/kg i.p.; filled square) was administered 15 minutes prior to intrathecal administration of 30 ng phenylephrine.
- Systemic phenylephrine induces tactile hypersensitivity in a dose ' dependent fashion. Phenylephrine (filled circle) was injected intraperitoneally at various doses.
- the ⁇ -1 antagonist, 5-MU (30 ug/kg i.p.; filled square) was administered 15 minutes prior to administration of 30 ng/kg phenylephrine.
- Spinal sulprostone, a selective EP 1 /EP 3 agonist induces chemical tactile hypersensitivity in a dose responsive fashion.
- Figure 2 shows that the increased sympathetic tone of ⁇ -2A and ⁇ -2C knockout mice enhances induction of tactile hypersensitivity by ⁇ -1 receptor activation.
- ildtype (filled circle) , ⁇ -2A knockout (filled square) , and ⁇ -2C knockout (filled triangle) mice were- injected intraperitoneally with increasing doses of phenylephrine and assayed for tactile hypersensitivity.
- ⁇ -2A knockout mice were pretreated with 50 mg/kg i.p. guanethidine to cause a temporary chemical sympathectomy 24-30 hours prior to an i.p. injection with phenylephrine (open square) .
- Each group of mice consisted of 5-6 animals.
- Th mean sensitization score and SEM were calculated and compared to a vehicle control group using an unpaired two-tailed t-test (* p ⁇ .01, ** p ⁇ .001) .
- Figure 3 shows that the sympathetic nervous system- enhances sulprostone-induc'ed tactile hypersensitivity.
- Wildtype (filled circle) , ⁇ -2A (filled square) , and ⁇ -2C (filled triangle) knockout mice were injected intrathecally with increasing doses of sulprostone and assayed for tactile hypersensitivity.
- ⁇ -2A knockout mice were pretreated with guanethidine (50 mg/kg i.p.) to cause a temporary chemical sympathectomy 24 hours prior to an intrathecal sulprostone injection (open square).
- Each group of. mice consisted of 5-6 animals.
- the mean sensitization score and SEM were calculated and compared to a vehicle control group using an unpaired two-tailed t-test (* p ⁇ .01, ** p ⁇ .001) .
- Figure 4 shows that ⁇ -2 knockout mice do not exhibit altered NMDA-induced tactile hypersensitivity.
- Wildtype (filled circle) , ⁇ -2A (filled square) , and ⁇ -2C (filled triangle) knockout mice were injected intrathecally with increasing doses of NMDA.
- Each group of 5-6 mice - was scored for tactile hypersensitivity.
- the mean response and SEM were calculated and compared to a vehicle control group using an unpaired two-tailed t-test (* p ⁇ .01, ** p ⁇ -001) .
- Figure 5 shows that ⁇ -adrenergic agonists differ in alleviation of sympathetically-enhanced sensory hypersensitivity.
- the response of 5-6 mice per group was scored; the mean response and SEM were calculated as described above.
- Each drug-treated group was compared to a vehicle coritrol group using- an unpaired two-tailed t-test (* p ⁇ .01, ** p ⁇ .001).
- (a) Spinal brimonidine and clonidine alleviate NMDA-induced tactile hypersensitivity in wildtype mice. Mice were injected intrathecally with DMSO vehicle or co-injected intrathecally with 100 ng NMDA and saline, 0.4 ⁇ g brimonidine (UK14304) or 1 ⁇ g ' clonidine.
- mice were injected intrathecally with DMSO vehicle or coinj ected intrathecally with 100 ng NMDA and saline, 0.4 ⁇ g brimonidine (UK14304) or 1 ⁇ g clonidine.
- Spinal brimonidine and clonidine differ in their ability ' to alleviate sulprostone-induced tactile hypersensitivity in the ⁇ -2C knockout mice.
- Mice were injected with DMSO vehicle or co-injected intrathecally with .200 ng ( -2C knockout) or 30 ng ( ⁇ -2A knockout) sulprostone and saline, 0.4 ⁇ g brimonidine (UK14304) or 0.4 ⁇ g clonidine.
- ⁇ -2 agonist analgesia is absent in the ⁇ -2A knockout mice; clonidine analgesia is also lost in the ⁇ -2C knockout mice.
- Figure 6 shows that brimonidine, but not clonidine or tizanidine, alleviates sulprostone-induced tactile hypersensitivity in the absence of sedation.
- the dose-responsive anti-hypersensitive and sedative ⁇ effects of three ⁇ -2 agonists (tizanidine, triangle; clonidine, square; and brimonidine, circle) were compared in models of sulprostone-induced tactile hypersensitivity and locomotor activity, respectively.
- the mean total sensitivity sc re and standard error of the mean was calculated and indicated as a solid line (left axis).
- Locomotor activity relative to vehicle-treated animals was expressed as a percentage, and the percent sedation calculated as 100% minus the percent locomotor activity and indicated as a hatched line (right axis) . . . . .
- Figure 7 shows variable ⁇ -2 vs. ⁇ -1 agonist selectivity in ⁇ -adrenergic agonists clonidine and brimonidine. Increasing concentrations of phenylephrine (filled square) , clonidine (filled
- ⁇ 5- diamond), tizanidine (filled circle), dexmeditomidine (filled triangle) and brimonidine (filled inverted triangle) were tested for ⁇ -1 and ⁇ -2 agonist activity using in vi tro cell-based functional assays.
- the increase in intracellular calcium in HEK cells stably expressing the bovine ⁇ -lA receptor (a) or the hamster ⁇ -lB receptor (b) following addition of various concentrations of ⁇ -adrenergic agonists was determined by measuring the change in fluorescence of a 5 calcium-sensitive dye.
- Agonists were tested 6-15 times in triplicate, and the mean fluorescence and SEM calculated at each concentration. Results from a typical experiment are shown.
- (c, d) ⁇ -2A and ⁇ -2C agonist activity of ⁇ -adrenergic agonists.
- Inhibition 0 of forskolin-induced cAMP accumulation in PC12 cells stably expressing the human ⁇ -2A receptor (c) or the human ⁇ -2C receptor (d) following addition of various -' concentrations of ⁇ -adrenergic agonists.
- Agonists were tested 3-5 times in triplicate, and the mean % 5 inhibition and SEM calculated at each concentration.
- Adrenergic receptors mediate physiological responses to the catecholamines, norephinephrine and epinephrine, and are members of the superfamily of G protein-coupled receptors having seven transmembrane domains. These receptors, which are divided pharmacologically into ⁇ -1, ⁇ -2 and ⁇ -adrenergic receptor types, are involved in diverse physiological functions including functions of the cardiovascular and central, nervous systems.
- the ⁇ -adrenergic receptors mediate most excitatory functions: ⁇ -1 adrenergic receptors generally mediate responses in the effector organ, while ⁇ -2 adrenergic receptors are located postsynaptically as well as presynaptically, where they ' regulate release of neurotransmitters.
- ⁇ -2 adrenergic receptors are used clinically in the treatment of hypertension, glaucoma, spasticity, and attention-deficit disorder, in the suppression of opiate withdrawal, and as adjuncts to general anesthesia.
- ⁇ -2 adrenergic receptors are presently classified into three subtypes based on their pharmacological and molecular characterization: ⁇ -2A/D * ( ⁇ -2A in human and ⁇ -2D in rat) ; ⁇ -2B; and ⁇ -2C (Bylund et al . , Pharmacol. Rev. 46:121-136 (1994); and Hein and Kobilka, Neuropharmacol . 34:357-366 (1995)).
- the ⁇ -2A and ⁇ -2B subtypes can regulate arterial contraction in some vascular beds, and the ⁇ -2A and ⁇ -2C subtypes mediate feedback inhibition of norepinephrine release from sympathetic nerve endings.
- the ⁇ -2A subtype also mediates many of the central effects of ⁇ -2 adrenergic agonists (Calzada and Artihano, Pharmacol. Res. 44: 195-208 (2001); Hein et al., Ann. NY Acad. Science 881:265-271 (1999); and Ruffolo (Ed.), ⁇ -Adrenoreceptors : Molecular Biology, Biochemistry and Pharmacology S. Karger Publisher's Inc. Farmington, CT (1991)).
- the autoinhibitory action on norepinephrine release is mediated through the ⁇ -2C receptor at low concentrations of norepinephrine, and through the ⁇ -2A receptor at high concentrations of norepinephrine
- clonidine was analgesic in wild type mice but not in ⁇ -2C knockout mice (compare Figures 5b and d) .
- clonidine nor brimonidine were analgesic in ⁇ -2A knockout mice, which lack the spinal ⁇ -2A adrenergic receptor which mediates analgesic activity.
- ⁇ -2C knockout mice treated with sulprostone which serve as a model for sympathetically-enhanced conditions
- the pan-agonists brimonidine and clonidine have strikingly different activities.
- brimonidine but not other pan-agonists such as tizanidine or clonidine, had analgesic activity without concomitant sedation (see Figure 6) .
- brimonidine was highly selective (more than 1000-fold) - for ⁇ -2 adrenergic receptors as compared to ⁇ -1 receptors in functional assays as compared to other pan-agonists such as clonidine and tizanidine, which exhibited less than 10-fold selectivity (see Figure 7 and Table 2) .
- Dyspepsia has been described as a biopsychosocial disorder and is generally characterized, in part, by epigastric discomfort following meals.
- dyspepsia can be characterized by early satiety, nausea, vomiting, abdominal distension, bloating, or anorexia in the absence of organic disease (Thumshirn, Gut 51 Suppl. 1: 163-66 (2002; Anderson, Dorland s Illustrated Medical Dictionary 28 th Edition, W.B. Saunder' s Company, Philadelphia (1994) ) .
- the methods of the invention can be useful for preventing o reducing the severity of dyspepsia, which, as- used herein, is a term which means impaired digestion.
- dyspepsia includes, without limitation, acid dyspepsia, which is associated with excessive acidity of the stomach; appendicular dyspepsia, also known as appendix dyspepsia, in which dyspeptic symptoms accompany chronic appendicitis; catarrhal dyspepsia, which is accompanied by gastric inflammation; chichiko dyspepsia, a condition of farinaceous malnutrition found in poorly nourished infants; cholelithic dyspepsia, which involves sudden dyspeptic attacks associated with gallbladder disturbance; colonic dyspepsia, which involves a functional disturbance of the large intestine; fermentive dyspepsia, which is characterized by fermentation of ingested food; flatulent dyspepsia, which is* associated with, the formation of gas in the stomach and often involves upper abdominal discomfort accompanied by frequent belching; gastric
- the methods of the invention are used to prevent or reduce the severity of dyspepsia other than dyspepsia associated with gastric inflammation.
- the invention relates to treating gastrointestinal disease.
- Inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) are gastrointestinal diseases which affect one-half of all Americans during their lifetime, at a cost of greater than $2.6 billion dollars for IBD and greater than $8 billion dollars for IBS.
- IBD Inflammatory bowel disease
- IBS irritable bowel syndrome
- the frequency or severity of visceral hypersensitivity associated with IBD, IBS and other gastrointestinal diseases including inflammatory gastrointestinal diseases is exacerbated by stress.
- the methods of the invention can be useful for preventing or reducing the severity of visceral hypersensitivity associated with a stress-associated gastrointestinal disease such as,- without limitation, ulcerative colitis (UC) , Crohn's disease (CD), or . irritable bowel syndrome (IBS).
- UC ulcerative colitis
- CD Crohn's disease
- IBS irritable bowel syndrome
- the present invention provides a method of preventing - or reducing the severity of visceral hypersensitivity associated with a stress-associated gastrointestinal disease in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof.
- tachycardia means excessive rapidity of heart rate and includes ' tachyarrhymthias . In adults, ' the ' term tachycardia generally refers to a heart rate of greater than 100 . beats per minute.
- tachycardia encompasses tachycardias secondary to a variety of disorders other than myocardial ischemia including, without limitation, paroxysmal tachycardia, in which the tachycardia is of sudden onset and cessation and either ventricular or supraventricular, and nonparoxysmal tachycardia, which is a tachycardia of slow onset, generally with a heart rate of 70 to 130 beats per minute.
- a method of the invention prevents or reduces the severity of an automatic tachycardia which is not associated with myocardial ischemia.
- a method of the invention prevents or reduces the severity of tachycardia in an adult subject.
- a method of the invention prevents or reduces the severity of tachycardia in a subject who is a child.
- Tachycardias to be treated according to a method of the invention include those originating fromany part of the heart such as ventricular tachycardias and supraventricular tachycardias, which can be classified, for example, into atrial and junctional (nodal) tachycardias.
- the methods of the invention can be useful for preventing or reducing the severity of, for example, ventricular tachycardias, which are abnormally rapid ventricular rhythms with aberrant ventricular excitation, often in excess of 150 beats per minutes, generated within the ventricle and sometimes occurring in conjun tion with atrioventricular dissociation.
- the methods of the invention further can be useful for preventing or reducing the severity of supraventricular tachycardias (SVT) , which are regular tachycardias in which the point of stimulation is located above the bundle branches such as in the sinus ' node, atria or atrioventricular junction or which arise from a large reentrant circuit including both atrial and ventricular sites.
- SVT supraventricular tachycardias
- a method of the invention is used to prevent or reduce the severity of an atrial tachycardia, which is characterized by a rapid cardiac rate generally between 160 and 190 beats per minutes an which originates from an atrial locus; such tachycardias include, but are not limited to, paroxysmal atrial tachycardias.
- a method of the invention is used to prevent or reduce the severity of a junctional tachycardia, which is a tachycardia arising in response to impulses originating in the atrioventricular junction and which is generally characterized by a heart rate greater than 75 beats per minute.
- Junctional tachycardias include nonparoxysmal and paroxysmal junctional tachycardias, such as junctional tachycardias resulting from reentry or enhanced automaticity.
- the methods also can be used to prevent or reduce the severity of, without limitation, double tachycardias, in which two types of ectopic tachycardia are involved; sinus tachycardias, which originate in the sinus node and can be associated with shock, hypotension, congestive heart failure or fever; orthostatic tachycardia, which is characterized by a disproportionate rapidity of heart rate upon rising from a reclining to a standing position; and chaotic atrial tachycardia, which is characterized by atrial rates of 100 to 130 beats per minute, markedly variable P wave morphology and irregular P-P intervals (Anderson, supra , 1994) .
- sinus tachycardias which originate in the sinus node and can be associated with shock, hypotension, congestive heart failure or fever
- orthostatic tachycardia which is characterized by a disproportionate rapidity of heart rate upon rising from a reclining to a standing position
- chaotic atrial tachycardia which is characterized by
- Tachycardias to be treated according to a method of the invention can be associated with one or more disorders such as pulmonary disease, diabetes, or surgical trauma and can occur, ' for ' example, in the elderly.
- chaotic atrial tachycardia multifocal atrial tachycardia
- nonparoxysmal junctional tachycardia can be associated, for example, with surgical trauma. It is understood that these and a variety of well known automatic and other tachycardias which are not associated with myocardial ischemia can be prevented or reduced in severity according to the methods of the invention.
- the invention provides a method of preventing or reducing the severity of tachycardias of all types including those associated with myocardial ischemia.
- the methods of the invention also can be useful for' preventing or reducing the severity of panic attack, a common disorder with a prevalence of around 3% in the general"'population (Potokar and Nutt, Int. J. Clin. Pract. 54: 110-114 (2000)).
- Panic disorder involving recurrent panic attacks is typically observed in young adults, with an average age of onset of 24 years, and is more common in females than in males.
- panic attack means a discrete, period of intense fear or discomfort accompanied by one or more of the following symptoms: accelerated heart rate or palpitation; chest pain; chills or hot flushes; derealization or depersonalization; fear of dying; fear of losing control or going crazy; dizziness or faintness; feelings of choking; nausea or abdominal distress; paraesthesia; sensations of shortness of breath or smothering; sweating; or trembling or shaking.
- a panic attack typically begins with the sudden onset of intense apprehension or fear and generally has a duration of about 5 to 20 minutes ' .
- panic attac encompasses both full-blown and limited-symptom attacks; full-blown attacks involve four or more of the above symptoms while limited-symptom attacks involve fewer than four symptoms.
- a method of the invention can entirely prevent a panic attack, or can prevent or reduce the severity of one or any combination of the attendant symptoms described above.
- panic attack encompasses panic disorder, which is defined as recurrent panic . attacks in conjunction with persistent concern over additional episodes or the consequences of the attacks or a notable change in behavior experienced for at least one month following one or more panic attacks.
- Panic disorder can be associated with other psychiatric conditions such as depression.
- brimonidine or a pharmaceuticallly acceptable salt, ester, amide, sterioisomer or racemic mixture thereof can be systemically administered to a subject in order to prevent or reduce the severity of type II diabetes in the subject.
- non-inflammatory dermatological condition means any dermatosis or other skin disease or condition that is not caused or accompanied by inflammation.
- a non-inflammatory dermatological condition to be treated according to a method of the invention can originate or be exacerbated under stressful conditions.
- Non-inflammatory dermatological conditions encompass, without limitation, non-inflammatory dermatoses including hon-inflammatory blistering diseases such as ep-idermolysis bullosa and porphyria; ichthyosis; keratosis pilaris;* juvenile plantar dermatosis (JPD) ; lichen plantus dermatosis; and xerosis.
- non-inflammatory dermatoses including hon-inflammatory blistering diseases such as ep-idermolysis bullosa and porphyria; ichthyosis; keratosis pilaris;* juvenile plantar dermatosis (JPD) ; lichen plantus dermatosis; and xerosis.
- JPD juvenile plantar dermatosis
- the invention provides a method of preventing or reducing the severity of a stress-associated inflammatory dermatological condition in a subject by systemically administering to the subject an effective amount of brimonidine or- a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof.
- Such methods can be useful, for example, in preventing or reducing the severity of one or more symptoms such as itching or other discomfort associated with the inflammatory dermatological condition.
- any of a variety of inflammatory dermatological conditions are encompassed by the methods of the invention including, without limitation, any of a variety of forms of acute or chronic dermatitis such as psoriasis, allergic dermatitis such as allergic contact dermatitis, atopic dermatitis, dermatitis calorica, contact dermatitis, 5 cosmetic dermatitis, eczema, exfoliative dermatitis, factitial dermatitis, irritant dermatitis, lichen simplex chronicus, marine dermatitis, neurodermatitis, ' p.erioral dermatitis, phototoxic dermatitis, seborrheic dermatitis, stasis dermatitis and dermatitis vegetans.
- acute or chronic dermatitis such as psoriasis, allergic dermatitis such as allergic contact dermatitis, atopic dermatitis, dermatitis calorica, contact dermatitis, 5 cosmetic dermatitis, ec
- the methods of the invention can be useful for preventing or reducing the severity of a variety of disorders of muscle contraction, which are conditions that result, at least in part, from inappropriate muscle contraction. Disorders of muscle contraction to
- disorders of skeletal muscle contraction disorders of smooth muscle contraction, disorders of muscle contraction associated with a gland, and disorders of cardiac muscle
- contraction such as congestive heart failure; these and other, disorders to be prevented or reduced in severity- according to a method of the invention include those in which the myocytes are innervated as well as those in which the myocytes are not innervated.
- contraction such as congestive heart failure; these and other, disorders to be prevented or reduced in severity- according to a method of the invention include those in which the myocytes are innervated as well as those in which the myocytes are not innervated.
- the methods of the invention can be useful for preventing or reducing the severity of a. disorder of muscle contraction such as back or other muscle spasm; muscle contraction associated with cystitis; muscle contraction associated with non-bacterial
- the methods of the invention can be useful, for example, for preventing or reducing the severity of a muscle spasm such as a back spasm.
- Muscle spasms are well known in the art.
- the term "spasm" means a sudden, involuntary contraction of a muscle or a group of muscles, accompanied by pain and interference with function.
- a spasm can produce, for example, involuntary movement or distortion.
- a method of the invention prevents or reduces the severity of a back spasm.
- cystitis means inflammation of the urinary bladder.
- cystitis encompasses, yet is not limited to, allergic cystitis, bacterial cystitis, acute catarrhal cystitis, cystic cystitis, diphtheritic (croupous) cystitis, eosinophilic cystitis, exfoliative cystitis, cystitis foilicularis, cystitis glandularis, incrusted cystitis, chronic interstitial (panmural, submucous) cystitis, mechanical cystitis, cystitis papillomatosa and cystitis senilis feminarum.
- Cystitis can be -accompanied by one or more of the following clinical symptoms: frequent urination, burning on urination, suprapubic discomfort, lassitude, cloudy or blood-tinged urine and sometimes low-grade fever (Bennett and Plum (Eds.), Cecil Textbook of Medicine Sixth Edition, W.B. Saunders Company, Philadelphia 1996) .
- a method of the invention also can be useful for preventing or reducing the severity of muscle contraction associated with non-bacterial prostatitis.
- non-bacterial prostatitis is synonymous with "abacterial prostatitis” and means inflammation of the prostate not resulting from bacterial infection.
- Non-bacterial prostatitis encompasses, yet is not limited ' to, chronic non-bacterial prostatitis, allergic or eosinophilic prostatitis and non-specific granulomatous prostatitis. It is understood that the term non-bacterial prostatitis includes, without limitation, prostatitis of unknown etiology characterized by abnormal expressed prostatic secretions (EPS) and normal bacterial cultures.
- EPS abnormal expressed prostatic secretions
- non-bacterial prostatitis can be effectively treated with antibiotics or stress management (Bennett and Plum, supra , 1996) . It is understood that muscle contraction associated with these or other, forms of mild, severe, acute or chronic non-bacterial prostatitis ⁇ can be treated according to a method of the invention.
- a method of the invention is useful for preventing or reducing the severity of muscle contraction associated with tension type headache (TTH) , which is a common form of headache affecting as many as 90% of adult Americans.
- tension type headache means a headache caused, at least in part, by muscle contraction, which may be triggered, for example, by stress or exertion.
- the term ' “tension type headache” encompasses episodic and chronic headache and includes but is not limited to common tension headaches.
- Tension type headaches generally involve the posterior of the head and neck, although they may also appear at the top or front of the skull and are further generally characterized by symmetry and a non-disabling severity.
- diagnostic features of tension type headache include bilateral pain; mild to moderate severity; pressing-like character with a stable profile; accentuation as the day progresses; possible high frequency such as daily or continuously; and relative rarity of migrainous features such as nausea, photosensitivity, phonosensitivity and aggravation by physical activity such as head movement.
- Tension type headaches result from tightening of muscles 'of the face, neck and scalp due, for example, to stress, overwork, eyestrain or poor posture. Such headaches can last for days or weeks and can cause pain of varying intensity. Tension type headaches occurring over an extended period of time such as several weeks or months are denoted chronic tension headaches and are encompassed by the term tension type headache as used herein.
- Tension type headaches can be distinguished from migraines by the absence of vascular features and - symptoms such as nausea, vomiting and sensitivity to light and the absence of an aura (Spira, Austr. Family Phvs. 27: 597-599 (1998).
- Thfe term .tension type headache which refers to headaches without a significant vascular component, is used in contradistinctio 'to tension-vascular headaches, cluster headaches, migrainous headaches and other headaches with a major vascular component.
- the methods of the invention also ' can be useful for preventing or reducing the severity of sensory hypersensitivity associated with other headaches including, but not limited to, cervicogenic headache, post-traumatic headache, cluster headache and temporomandibular joint disorder (TMJ) .
- the methods of the invention also can be useful for preventing or reducing the severity of sensory hypersensitivity associated with migraine, a headache that plagues more than 10% of the population and that may be associated with a vascular component.
- the methods of the invention prevent or reduce the severity of an ocular hypersensitivity associated with migraine, for example, photophobia.
- the methods of the invention are useful for preventing or reducing the severity of sensory hypersensitivity associated with any of a variety of forms of migraine including, but not limited to, migraine without aura ("MO”) , migraine with aura (“MA”) , and migrainous disorder.
- Sensory hypersensitivity to be prevented or reduced in severity according to a method of the invention further can be associated with, for example, abdominal migraine, acute confusional migraine, basilar (basilar artery) migraine, hemiplegic or familial hemiplegic migraine, fulgurating migraine, ocular (ophthalmic) migraine, ⁇ phthal oplegic migraine or retinal migraine.
- the methods of the invention can be useful for preventing or reducing the severity of sensory hypersensitivity associated with a migraine equivalent, in which* there is a migraine aura without headache.
- Migraine auras are the abnormal visual, motor, psychic, paresthesic or other neurologic abnormalities that accompany a migraine. See Elrington, J. Neurol. Neurosurq. Psychiatry 72 Supple. II:iilO-iil5 (2002); Anderson, supra , 1994; Bennett and Plum, supra , 1996.
- the methods of the invention can be useful ⁇ for preventing or reducing the severity of one or more of a variety of types of sensory hypersensitivity associated with migraine.
- Such sensory hypersensitivity includes, but is not limited to, nausea; vomiting; diarrhea; photophobia (light intolerance) ; and phonophobia (noise intolerance) .
- Such sensory hypersensitivity also includes visual abnormalities such as bright flashing lights (scintillation or fortification scotomata) or a monocular (retinal) visual abnormality or hemianoptic loss of vision; paresthesia (abnormal touch sensation) ' such as unilateral paresthesia; aphasia (loss of speech or comprehension)-; hemiparesis (muscular weakness or incomplete paralysis on one side of the body) ; hemisensory defect; or vertigo, ataxia (loss of muscular coordination) or diplopia. It is understood that the methods o-f the invention can be useful for preventing or reducing the severity of one of these or other types of sensory hypersensitivity occurring prior to, during, or subsequent to migraine headache, or occurring in the absence of headache as part of a migraine equivalent.
- Fibromyalgia is a disorder involving chronic, widespread musculoskeletal pain and tenderness at multiple sites in , the absence of signs of connective tissue or other musculoskeletal disease.
- fibromyalgia is defined by pain or tenderness at 11 of 18 or more si ' tes as defined by the American College of Rheumatology. Fibromyalgia frequently is associated with disturbed sleep, chronic fatigue, headaches and irritable bowel syndrome (Bennett and Plum, supra , 1996) .
- a variety of types of sensory hypersensitivity can be associated with fibromyalgia and can be prevented or reduced in severity according to a method of the invention, including, without limitation, hypersensitivity to light, noise, touch or odors, cold or heat intolerance, nausea or allergic-like symptoms such as rhinitis, itching, or rash in the absence of a true allergy.
- a method of the invention including, without limitation, hypersensitivity to light, noise, touch or odors, cold or heat intolerance, nausea or allergic-like symptoms such as rhinitis, itching, or rash in the absence of a true allergy.
- the methods of the invention can be useful for preventing or reducing the severity of any of these or other types of sensory hypersensitivity associated with fibromyalgia.
- a stress-associated behavioral disorder which is any behavioral disorder which is induced or exacerbated by stress.
- a stress-associated- behavioral disorder can be a compulsive or repetitive detrimental behavior which is -induced or exacerbated by stress such as, without limitation, over-eating or obesity, obsessive compulsive disorder (OCD) , tics, Tourette syndrome (TS) , alcohol use, drug use, gambling, self-inflicted injurious behavior such as scratching or hair-pulling, or sexual impotency or arousal.
- OCD obsessive compulsive disorder
- TS Tourette syndrome
- alcohol use drug use
- gambling gambling
- self-inflicted injurious behavior such as scratching or hair-pulling, or sexual impotency or arousal.
- the stress-associated behavioral disorder is a disorder other than drug use.
- the stress-associated behavioral disorder is a disorder other than drug or alcohol use.
- the methods of the invention further can be useful for preventing or reducing the severity of a stress-associated psychiatric disorder, which is any psychiatric disorder which is induced or exacerbated by stress.
- a stress-associated psychiatric disorder which is any psychiatric disorder which is induced or exacerbated by stress.
- the methods of the invention can be used to prevent or reduce the severity of a psychiatric disorder such as schizophrenia.
- brimonidine can act as a neuroprotective agent, preventing, for example, retinal damage in a number of ocular conditions affecting the neurosensory retina.
- - Ocular conditions which can be prevented or reduced in severity using brimonidine according to a method of the invention include,” without limitation, diabetic retinopathy; macular edema such as macular edema associated with diabetes mellitus or other conditions; retinal degeneration such as age-related macular degeneration or .retinitis pigmentosa; inflammatory disorders of the retina; vascular occlusive conditions of the retina such as retinal vein occlusions or.
- retinopathy of prematurity retinopathy associated with blood disorders such as sickle cell anemia
- damage following retinal detachment damage or insult due to vitrectomy surgery or retinal surgery
- artd other retinal damage including therapeutic damage such as that resulting from laser treatment of- the retina, for example, pan-retinal photocoagulation for diabetic retinopathy or photodynamic therapy of the retina, for example, for age-related macular degeneration as well as other ocular conditions such as ocular itch.
- Ocular conditions that can be -prevented or reduced in severity according to a method of the invention further include, without limitation, genetic and acquired optic neuropathies such as optic neuropathies characterized primarily by loss of central vision, for example, Leber's hereditary optic neuropathy (LHON), autosomal dominant optic atrophy (Kjer disease) and other optic neuropathies such as those involving mitochondrial defects, aberrant dynamin-related proteins or inappropriate apoptosis.
- LHON Leber's hereditary optic neuropathy
- Kjer disease autosomal dominant optic atrophy
- other optic neuropathies such as those involving mitochondrial defects, aberrant dynamin-related proteins or inappropriate apoptosis. See, for example, Carelli et al., Neuroche . Intl. 40:573-584 (2002); and Olichon et al., J. Biol. Chem. 278:7743-7746 (2003).
- the methods of the invention can be useful for preventing or reducing the severity of a stress-associated condition without concomitant sedation.
- Sedation is a term that means a reduction in motor activity.
- the phrase "without concomitant sedation,” as used herein, means that relatively little reduction in motor activity accompanies the reduction in severity of one or more symptoms of a stress-associated condition at one or more doses of drug.
- a drug generally acts "without concomitant sedation” if, upon peripheral administration, the dose required to produce a 20% reduction in motor activity is at least 3-fold greater than the dose required to produce a significant reduction in one or more symptoms of the stress-associated condition.
- brimonidine but not tizanidirfe or clonidine could be administered at doses that produced a reduction in the sensitization score (solid line, left axis) with less than a 20% increase in sedation (broken line, right axis) .
- the dose required to produce a 20% reduction in motor activity can be at least 4-fold greater than, 5-fold greater than, 6-fold greater than, 7-fold greater than, 8-fold greater than, 9-fold greater than, 10-fold greater than, 25-fold greater than, 50-fold greater than, 100-fold greater than, 200-fold greater than, 500-fold greater than, 1000-fold greater than, 2000-fold greater than, or 5000-fold greater than the dose required to produce a significant reduction in one or more symptoms of a stress-associated condition.
- Methods of determining the extent of a reduction in severity of symptoms of a stress-associated condition and the extent of sedation are well known in the art.
- brimonidine means a compound having the formula
- brimonidine encompasses, without limitation, AlphaganTM and UK14304.
- Brimonidine, and pharmaceutically acceptable salts, ,. esters, amides, sterioisomers and racemic mixtures thereof is commercially available, for example, as AlphaganTM (Allergan) .
- brimonidine and pharmaceutically acceptable salts, esters, amides, sterioisomers and racemic mixtures thereof can be prepared by routine methods as described below in Example I. See, also, U.S. Patent No. 6,323,204.
- Suitable pharmaceutically acceptable salts of brimonidine include, without limitation, acid addition salts, which can be formed, for example, by mixing a solution of brimonidine with a solution of an appropriate acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- an appropriate acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- Pharmaceutically acceptable salts further include, yet are not limited to, acid phosphate, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroiodide, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-
- a method of the invention is practiced with brimonidine tartrate.
- functional groups of brimonidine can be modified, for example, to enhance the pharmacological utility of the compound.
- modifications which are well within the knowledge of the skilled chemist and include, without limitation, esters, amides, ethers, N-oxides, and pro-drugs of brimonidine, are encompassed within the term "brimonidine” as used herein.
- modifications that can enhance activity include, for example, esterification such as the formation of C x to C 6 alkyl esters, preferably C x to C 4 alkyl esters, wherein the alkyl group is a straight or branched chain.
- esters include, for example, C 5 to C 7 cycloalkyl esters and arylalkyl esters such as benzyl esters. Such esters can be prepared from the compounds described herein using conventional methods well known in the art of organic chemistry.
- amides include, for example, those derived from ammonia; primary C x to C 6 dialkyl amines, where the alkyl groups are straight or branched chain; and arylamines having various substitutions.
- the amine also can be in the form of a 5 or 6 membered ring. Methods for preparing these-, and other amides are well known in the art.
- brimonidine chemically distinct enantiomers and tautomers of brimonidine are encompassed within the term "brimonidine” and can be useful in the methods of the invention.
- a compound in crystalline form, may exist as polymorphs; in the presence of a solvent, a compound may form a solvate, for example, with water or a common organic solvent.
- Such polymorphs, hydrates and other solvates of brimonidine also are encompassed within the term "brimonidine” and can be useful in the methods of the invention disclosed herein.
- compositions containing brimonidine can be useful in the methods of the invention.
- a pharmaceutical composition includes brimonidine and optionally includes an excipient such as a pharmaceutically acceptable carrier or a diluent, which is any carrier or diluent that has substantially no long term or permanent detrimental effect when administered to a subject.
- An excipient generally is mixed with active compound, or permitted to dilute or enclose the active compound.
- a carrier can be a solid, semi-solid, or liquid agent that acts as an excipient or vehicle for the active compound.
- solid carriers include, without limitation, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, polyalkylene glycols, talcum, cellulose, glucose, sucrose and magnesium carbonate.
- Suppository formulations can include, for example, propylene glycoi as a carrier.
- pharmaceutically acceptable carriers and diluents include,, without . limitation, water, such as distilled or deionized water; saline; aqueous dextrose, glycerol, ethanoi and the like. It is understood that the active ingredients can be soluble ' or can be delivered as a suspension in the desired carrier or diluent.
- a pharmaceutical composition also can optionally include one or more agents such as, without limitation, emulsifying agents, wetting agents, sweetening or flavoring agents, tonicity adjusters, ⁇ preservatives, buffers or anti ' -ox ' idants .
- Tonicity adjustors useful in a pharmaceutical composition include, but are not limited to, salts such as sodium acetate, sodium chloride, potassium chloride, mannitol or glycerin and other pharmaceutically acceptable tonicity adjustors.
- Preservatives useful in pharmaceutical compositions include, without limitation, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate, and phenylmercuric nitrate.
- a pharmaceutical composition including, but not limited to, acetate buffers, citrate buffers, phosphate buffers and borate buffers.
- anti-oxidants useful in pharmaceutical compositions are well known in the art and include, for example, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytol ⁇ ene. It is understood that these and other substances known in the art of pharmacology can be- included in a pharmaceutical composition useful in the methods of the invention. See, for example, Remington' s Pharmaceutical Sciences Mack Publishing Company, Easton, PA 16 th Edition 1980.
- a composition containing brimonidine may be administered- in conjunction with one or more other therapeutic substances, in the same or different- pharmaceutical composition and by the same or different routes of administration.
- Brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioiso*mer or .racemic mixture thereof, is administered in an effective amount.
- Such an effective amount generally is the minimum dose necessary to achieve the desired prevention or reduction in severity of one or more symptoms of a stress-associated condition, for example, that amount roughly necessary to reduce the discomfort caused by the stress-associated condition to tolerable levels.
- Such a dose generally is in the range of 0.1-1000 mg/day and can be, for example, in the range of 0.1-500 mg/day, 0.5-500 mg/day, 0.5-100 mg/day, 0.5-50 mg/day, 0.5-20 mg/day, 0.5-10 mg/day or 0.5-5 mg/day, with the actual amount to be administered determined by a physician taking into account the relevant circumstances including the severity and type of stress-associated condition, the age and weight of the patient, the patient's general physical condition, and the pharmaceutical formulation and route of administration.
- Suppositories and extended release formulations also can be useful in the methods of the invention, including, for example, dermal patches, formulations for deposit on or under the skin and formulations for intramuscular injection.
- a pharmaceutical composition useful in the methods of the invention can be administered to a subject by a variety of means depending, for example, on the type of condition to be treated, the pharmaceutical formulation, and the history, risk factors and symptoms of the subject.
- Routes of administration suitable for the methods of the invention include both systemic and local administration.
- a pharmaceutical composition useful for preventing or reducing the severity of a stress-associated condition can be administered orally; parenterally; by subcutaneous pump; by dermal atch; by intravenous, intra-articular, subcutaneous or intramuscular injection; by topical drops, creams, gels or ointments; as an implanted or injected extended release formulation; by subcutaneous minipump or other implanted device; by intrathecal pump or injection; or by epidural injection.
- brimonidine can be incorporated in any pharmaceutically acceptable dosage form such as, without limitation, a tablet, pill, capsule, suppository, powder, liquid, suspension, emulsion, aerosol or the like, and can optionally be packaged in unit dosage form suitable for single administration of precise dosages, or sustained release dosage forms for continuous controlled administration.
- a method of the invention can be practiced by peripheral administration of brimonidine, or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof.
- peripheral administration or “administered peripherally” means introducing- brimonidine, or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof, into a subject outside of the central nervous system.
- Peripheral adminis'tration encompasses any route of administration other than direct administration to the spine or brain.
- Peripheral administration can be local or systemic. Local administration results in significantly more of. a pharmaceutical composition being delivered to and about the site of local administration than to regions distal to the site of administration. Systemic administration results in delivery of a pharmaceutical composition essentially throughout at least the entir peripheral system of the subject.
- peripheral administration useful in the methods of the invention encompass, without limitation, oral administration, topical administration, intravenous of other injection, and implanted minipumps or other extended release devices or formulations.
- a pharmaceutical composition useful in the invention can be peripherally administered, for example, orally in any acceptable form such as in a tablet, liquid, capsule, powder, or the like; by intravenous, intraperitoneal, intramuscular, subcutaneous or parenteral injection; by transdermal diffusion or electrophoresis; topically in any acceptable form such as in drops, creams, gels or ointments; and by minipump or other implanted extended release device or formulation.
- 6-Aminoquinoxaline (2.08 g, 14.4 mmol) was dissolved in 11.5 ml glacial acetic acid. The solution was cooled in water while a solution of bromine (0.74 ml, 2.3 g, 14.4 mmol) in 1.5 ml gl.acial acetic acid was added slowly over 15 minutes. After stirring for an additional 30 minutes, the orange red solid formed was filtered off and washed thoroughly with dry ether. The solid was dried in vacuo overnight to yield 4.44 g crude -product (a yield of 100%) . The compound, 6- amino-5-bromoquinoxaline hydrobromide, had no definite • melting point. A phase change from fine powder to red crystals was observed at about 220° C. Decomposition. was. observed at about 245° C. The material was used directly for preparation of 6-amino-5-bromoquinoxaline as follows.
- 6-Amino-5-Bromoquinoxaline Crude 6-amino-5-bromoquinoxaline from above was dissolved in water, and saturated sodium bisulfite solution was added until the resulting solution tested negative with starch-iodide paper. The solution was then basified with 2N sodium hydroxide and extracted throroughly-with ethyl acetate. The organic extract was dried over magnesium sulfate and concentrated under reduced pressure to give the free base. The crude product was recrystallized from boiling benzene to give yellow crystals, m.p. 155-6° C. Using various. analytical procedures, the yellow crystals were determined to be 6-amino-5-bromoquinoxaline. The yield was 82%.
- the aqueous phase was cooled to 0° C and basified with 6N sodium hydroxide, keeping the temperature of the solution below 15' C at all times.
- the yellow solid which precipitated was filtered off and washed thoroughly with water until the washings were neutral to pH paper.
- the solid was dried overnight in vacuo to give 1.97 g yellow solid, m.p. 249-250° C. The recovery was about 88%.
- phenylephrine an ⁇ -1 adrenergic receptor agonist
- intrathecal (i.t.) or intraperitoneal (i.p.) dosing- of phenylephrine caused tactile hypersensitivity, with significant responses observed starting at doses of 3 ng i.t. and 3 ng/kg i.p.
- Induction of tactile hypersensitivity was ⁇ -1 receptor dependent, as evidenced by the ability of the ⁇ -1 receptor antagonist 5-methyl urapidil (5-MU) to block the hypersensitive response when injected intraperitoneally.
- 5-methyl urapidil 5-methyl urapidil
- a set of pharmacological agents was assayed for the ability to prevent or ameliorate tactile hypersensitivity.
- -each receptor antagonist (5-MU, the EPi receptor antagonist or memantine) blocked only tactile hypersensitivity resulting from the corresponding receptor agonist (phenylephrine, sulprostone or NMDA, respectively) .
- Gabapentin which- is used clinically to alleviate neuropathic pain by reducing spinal . sensitization, also .was assayed-, for theability to block tactile hypersensitivity.
- Gabapentin inhibited tactile hypersensitivity elicited by sulprostone and NMDA, but not by phenylephrine, further demonstrating differences between the sensory pathways involved by different stimuli 1 .
- ⁇ -2 knockout mice were provided by Dr. Brian Kobilka (Stanford University; Link et al., Mol. Pharmacol . 48:48-55 (1995); Altman et al., Mol. Pharmacol . 56:154-161 (1999)).
- the ⁇ -2 knockout mice have C57BL/6 background and were bred from homozygous knockout mice breeding pairs. Age and sex matched C57BL/6 wildtype mice, were used as controls.
- 5-methylurapidil, brimonidine, phenylephrine, clonidine and guanethidine were obtained from Sigma and ⁇ dissolved in saline. Prazosin (Sigma) and tizanidine (Biomol; Plymouth Meeting, PA) were dissolved in distilled water.
- a sterile 30-gauge inch needle attached to a microsyringe was inserted between the L5 and L6 vertebrae.
- the mouse was held firmly by the pelvic girdle in one hand, while the syringe was held in the other hand at an angle of approximately 20° above the vertebral column.
- the needle was inserted into the tissue to one side of the L6 spinous process, into the groove between the spinous and transverse processes.
- the needle angle was decreased to about 10°, and the needle slowly advanced forward into the intervertebral space until a pop was felt and there was a visible serpentine tail movement.
- Compounds were slowly injected in the subarachnoid space in a volume of 5 ⁇ l. Each compound was tested at multiple doses. The minimal efficacious dose was used for all subsequent experiments.
- Sensitivity to light touch was quantified by scoring the response ' of mice to light stroking of their flanks with a small paintbrush, which is not normally painful.
- the mice were rated on the following scale once every 5 minutes between 15 and 50 minutes post injection: a score of "2 V was given to animals showing- aggressive escape responses along with squeaking and biting at the brush; a score of "1” was given to animals exhibiting mild squeaking with attempts to escape; and a score of "0” was given if the animal showed no response to the light stroking of the paintbrush.
- the scores were summed to generate a cumulative score of 0 to 16 a*s described in Minami et al., Pain 57:217-223 (1994). Statistical calculations of significance for in vivo studies were done using a two-tailed Students t-test.
- Guanethidine sympathectomies were performed essentially as follows. Animals were injected intraperitoneally with 50 mg/kg guanethidine (Malmberg and Basbaum, Pain 76:215-222 (1998)) before being assessed for baseline tactile sensitivity 24 hours later. Animals that exhibited normal tactile sensitivity were assayed for sensitivity to chemical induction of tactile hypersensitivity. Mice recovered from the sympathectomy six to eight days later as demonstrated by a return to pre-sympathectomy responsiveness.
- ⁇ -2A and ⁇ -2C knockout mice were compared to the sensitivity of wildtype mice.
- the ⁇ -2A and ⁇ -2C knockout mice did not exhibit baseline tactile hypersensitivity when compared to wildtype controls.
- concentration of phenylephrine that elicits " tactile hypersensitivity was compared in the knockout and wildtype mice. As shown in Figure 2, there was a dramatic leftward shift in the phenylephrine dose response in both the ⁇ -2A and ⁇ -2C knockout mice.
- guanethidine results in a functional sympathectomy by depleting noradrenaline from sympathetic terminals.
- ⁇ -2A knockout mice were chemically sympathecto ized by guanethidine treatment (50 mg/kg i.p.) and assayed for phenylephrine-induced sensitivity 24-30 hours later.
- guanethidine-treated ⁇ -2A mice the increased sensitivity to phenylephrine was partly ablated so that the dose response was similar to the biphasic dose response observed in wildtype mice (see Figure 2) .
- the dose response of sulprostone was identical in the wildtype and ⁇ -2C knockout mice, but was shifted to the left in the ⁇ -2A knockout mice.
- a 30 ng dose was maximally effective in the ⁇ -2A knockout mice compared to a partially hypersensitivity-inducing dose of 100 ng and a maximal dose of 200 ng in the wild-type and ⁇ -2C knockout mice.
- a guanethidine (50 mg/kg i.p.) chemical sympathectomy decreased the sensitivity of the ⁇ -2A knockout mice to sulprostone.
- the dose response of sulprostone-induced tactile hypersensitivity was shifted approximately 10-fold to the right in the ⁇ -2A knockout mice treated with guanethidine.
- ⁇ -adrenergic agonists differ in their ability to alleviate sensory hypersensitivity that is enhanced by the sympathetic nervous system.
- A. Brimonidine but not clonidine , alleviates sympa thetically-enhanced tactile hypersensitivity
- ⁇ -2 adrenergic agonists alleviate neuropathic pain through a spinal ⁇ -2A receptor.
- ⁇ -2 knockout mice alters the analgesic activity of the ⁇ -2 agonists.
- the ⁇ -2 agonists brimonidine and clonidine were first tested in the NMDA model in which sensitization is not influenced by -the basal sympathetic tone of. the knockout mice.
- Intrathecal co-administration of NMDA with either clonidine or brimonidine resulted in complete inhibition of tactile hypersensitivity in the. wildtype and ⁇ -2C ( Figures 5a and c, respectively) knockout mice.
- Sedation limits the utility of many pharmaceuticals, including ⁇ -2 agonists.
- the ⁇ -2 agonists were therefore compared to test whether there was a difference in the dose that resulted in alleviation of sensory hypersensitivity relative to the dose that resulted in sedation.
- ⁇ -2 agonists tizanidine, clonidine and brimonidine
- sedative effects and the ability to block tactile hypersensitivity were compared at various doses in models of locomoter activity and sulprostone-induced tactile hypersensitivity, respectively.
- the tactile hypersensitivity of 5-6 mice per group was scored every five minutes between 15 and" 50 minutes following intraperitoneal dosing. Vehicle treated animals typically had a score of about 4.
- the locomoter activity of 5-6 mice per group was measured in a five minute period 30 minutes following intraperitoneal dosing.
- the locomoter activity relative to vehicle-treated animals was expressed as a percentage; percentage sedation was calculated as 100% minus the percent locomoter activity.
- ⁇ -adrenergic receptor pharmacological profiles of brimonidine and clonidine were analyzed in assays using cell lines stably expressing ⁇ -2A, ⁇ -2C, ⁇ -lA and ⁇ -lB receptors. Consistent with previous studies, the order of potency for inhibiting forskolin-induced cAMP accumulation in PC12 cells stably expressing either ⁇ -2A or ⁇ -2C receptor ( Figures 7a, b; Table 2) was dexmedetomidine, which was greater than or equal to brimonidine, which was .greater than clonidine, which was greater than tizanidine, which was greater than or equal to phenylephrine (Jasper et al . , Biochem.
- ⁇ -2 agonists were partial agonists while brimonidine exhibited weak activity at the ⁇ -lA receptor and no activity at the ⁇ -lB receptor.
- clonidine and tizanidine have previously been characterized as " ⁇ -2 selective" agonists in binding assays, these compounds display a less than 10-fold selectivity between ⁇ -2 and ⁇ -1 receptor activation in functional assays.
- dexmedetomidine was approximately 300-fold selective in functional assays, and brimonidine, the most highly selective compound in functional assays, exhibited greater than 1000-fold selectivity for ⁇ -2 receptors relative to ⁇ -1 receptors (see Table 2) .
- Stable cell lines expressing an adrenergic receptor were established as follows.
- the bovine ⁇ -lA, hamster ⁇ -lB, human ⁇ -2A and human ⁇ -2C receptor cDNAs were blunt-end subcloned into the Nhel-EcoRI sites ' in the retroviral vector pCL BABE Puro.
- the retroviral . constructs were verified by double stranded DNA sequencing.
- High titer pseudotyped retroviral particles were produced by co-transfecting HEK293GP, a HEK293 cell line stably expressing Gag-Pol of the Maloney leukemia virus, with the appropriate retroviral vector and pMD.G, an expression vector for the vesicular stomatitis virus envelope protein, VSV-G.
- the media (DMEM, 10% FCS) was changed; the high titer (-1 X 10 6 pfu/mL) media was then harvested forty-eight hours later.. The supernatant was filtered through a 0.4 uM filter.
- the human ⁇ -2A and ⁇ -2C receptor supernatants were added, in varying . amounts, to naive PC12 cells, which were then incubated for 48 hours.
- the transduced cell populations were replated at a lower density and grown in media containing 100 ⁇ g/ml puromycin. Non-transduced cells were killed within three days, and single foci grew within two months. The foci were picked, expanded, and assayed for receptor density by brimonidine radioligand binding. Functional ⁇ -2 receptor activity was confirmed by inhibition of forskolin-induced cAMP accumulation.
- the bovine ⁇ -lA and hamster ⁇ -lB receptor supernatants were added, in varying amounts, to naive HEK293 cells, which were then ' incubated for 48 hours.
- the transduced cell populations were replated at a lower density and grown in media containing 0.25 ug/ml puromycin. Significant cell death was evident within three days, with single foci appearing within two weeks. After the foci were picked and expanded, expanded subclones were functionally assayed for ⁇ -1 receptor expression by measuring phenylephrine-induced intracellular Ca +2 accumulation. Receptor density was measured in a prazosin radioligand binding assay.
- Intracellular Ca +2 responses were measured as follows in HEK293 cells stably expressing either the bovine ⁇ -lA or hamster ⁇ -lB adrenergic receptor. Between 40,000 to 50,000 cells were plated per well in 96-well poly-D-lysine coated plates in 0.2 ml DMEM containing 10% heat-inactivated fetal calf serum, 1% antibiotic- antimycotic and 0.25 ⁇ g/ml puromycin one day prior to use.
- Intracellular cAMP measurement was performed as follows. PC12 cells stably expressing the human ⁇ -2A or human ⁇ -2C adrenergic receptors were plated in 96-well poly-D-lysine coated plates at a density of 30,000 cells per. ell in 100 ⁇ l DMEM supplemented with 10% horse serum, 5% heat inactivated fetal bovine serum, 1% antibiotic-antimycotic and 100 ⁇ g/ml puromycin. Cells were grown overnight at 37°C and -5% C0 2 .
- Cells were dosed by adding an equal volume of media containing IBMX (to a final concentration of 1 mM) , forskolin (to a final concentration of 10 ⁇ M) and the appropriate drug dilution (to a final concentration of between 10 ⁇ 5 M and 10 "12 M) . After a 10 minute incubation, the media was aspirated and the cells lysed with 200 ⁇ l lysis buffer (Amersham Biosciences;
- the percent efficacy was determined by comparing the maximum effect of the compound to the effect of a standard full agonist, which was phenylephrine for ⁇ -1 receptors and brimonidine for ⁇ -2 receptors .
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/607,439 US20040266776A1 (en) | 2003-06-25 | 2003-06-25 | Methods of preventing and reducing the severity of stress-associated conditions |
PCT/US2004/020194 WO2005002580A1 (en) | 2003-06-25 | 2004-06-22 | Use of brimonidine for preventing and reducing the severity of stress-associated conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1638569A1 true EP1638569A1 (en) | 2006-03-29 |
EP1638569B1 EP1638569B1 (en) | 2012-01-04 |
Family
ID=33540268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04755981A Expired - Lifetime EP1638569B1 (en) | 2003-06-25 | 2004-06-22 | Use of brimonidine for preventing and reducing the severity of stress-associated conditions |
Country Status (15)
Country | Link |
---|---|
US (6) | US20040266776A1 (en) |
EP (1) | EP1638569B1 (en) |
JP (2) | JP2007524625A (en) |
KR (1) | KR20060023575A (en) |
CN (2) | CN102579448A (en) |
AT (1) | ATE539751T1 (en) |
AU (2) | AU2004253500A1 (en) |
BR (1) | BRPI0411826A (en) |
CA (1) | CA2530487C (en) |
DK (1) | DK1638569T3 (en) |
ES (1) | ES2376878T3 (en) |
HK (1) | HK1090282A1 (en) |
MX (1) | MXPA05013900A (en) |
TW (1) | TWI371276B (en) |
WO (1) | WO2005002580A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005115395A2 (en) | 2004-05-25 | 2005-12-08 | Sansrosa Pharmaceutical Development, Inc. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
AU2002236495B2 (en) | 2000-11-29 | 2006-05-11 | Allergan, Inc. | Intraocular implants for preventing transplant rejection in the eye |
US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
US20050059744A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
US20100266638A1 (en) * | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
US8802128B2 (en) | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
WO2008144399A1 (en) * | 2007-05-18 | 2008-11-27 | Bausch & Lomb Incorporated | COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS |
ES2463717T3 (en) * | 2007-07-27 | 2014-05-29 | Galderma Laboratories Inc. | Compounds, formulations, and methods to reduce wrinkles, folds and sagging skin |
US20090061020A1 (en) * | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
WO2009052073A2 (en) | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists |
US20110269805A1 (en) * | 2007-10-18 | 2011-11-03 | Gil Daniel W | Method of treating sensorimotor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione |
US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
ES2518418T3 (en) | 2008-08-01 | 2014-11-05 | Eye Therapies Llc | Vasoconstriction compositions and methods of use |
US20100203165A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
WO2011028621A1 (en) * | 2009-08-26 | 2011-03-10 | Allergan, Inc. | Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists |
CN102724951A (en) | 2009-11-09 | 2012-10-10 | 阿勒根公司 | Compositions and methods for stimulating hair growth |
EP2329849B1 (en) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
WO2011075621A1 (en) * | 2009-12-17 | 2011-06-23 | Alpha Synergy Development, Inc. | Compositions and methods for ophthalmic delivery of nasal decongestants |
PT2552449T (en) | 2010-03-26 | 2017-06-12 | Galderma Res & Dev | Compositions comprising brimonidine for the treatment of erythema |
CN103096894A (en) | 2010-03-26 | 2013-05-08 | 盖尔德马研究及发展公司 | Improved methods and compositions for safe and effective treatment of telangiectasia |
US20120073515A1 (en) * | 2010-09-28 | 2012-03-29 | Advanced Bionics Corporation | Intrathecal needle guide apparatus |
SI2444068T1 (en) | 2010-10-21 | 2014-11-28 | Galderma S.A. | Brimonidine gel composition |
US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
US8445526B2 (en) | 2011-02-03 | 2013-05-21 | Glaucoma & Nasal Therapies Llc | Compositions and methods for treatment of glaucoma |
US9144600B2 (en) | 2011-07-14 | 2015-09-29 | Allergan, Inc. | Methods for treatment of incontinence associated with sexual activity |
EP2956096A1 (en) | 2013-02-15 | 2015-12-23 | Allergan, Inc. | Sustained drug delivery implant |
US8999938B2 (en) | 2013-06-21 | 2015-04-07 | Gnt Llc | Ophthalmic lipophilic drug delivery vehicle formulations |
EP3226972A4 (en) * | 2014-12-01 | 2018-08-08 | Achelios Therapeutics, Inc. | Methods and compositions for treating migraine and conditions associated with pain |
SG11202100985QA (en) * | 2018-08-29 | 2021-03-30 | Cellix Bio Private Ltd | Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5380754A (en) * | 1988-02-29 | 1995-01-10 | Virotex Corporation | Topical composition enhancing healing of viral lesions |
EP1285657A3 (en) * | 1993-10-13 | 2003-08-20 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US6323204B1 (en) * | 1993-10-13 | 2001-11-27 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US6462077B1 (en) * | 1993-12-28 | 2002-10-08 | Allergan, Inc. | Thromboxane ligands without blood clotting side effects |
GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
WO1996025163A1 (en) | 1995-02-14 | 1996-08-22 | Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center | Treatment of herpes simplex viruses |
US6194415B1 (en) * | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
WO1999030690A1 (en) | 1997-12-15 | 1999-06-24 | Axia Therapeutics, Inc. | Oral delivery formulation |
US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
DK1124535T3 (en) | 1998-10-27 | 2003-01-06 | Alcon Lab Inc | Preservative system for topically deliverable pharmaceutical compositions containing a fatty acid / amino acid soap |
AU768393B2 (en) * | 1999-05-28 | 2003-12-11 | Jeffrey Berlant | Compounds and methods for the treatment of post traumatic stress disorder |
AU5331200A (en) | 1999-06-11 | 2001-01-02 | Ohio State University Research Foundation, The | Methods and compositions for treating raynaud's phenomenon and scleroderma |
KR100331529B1 (en) | 1999-06-16 | 2002-04-06 | 민경윤 | Composition for Oral Administration of Hardly Soluble Antifungal Agent and Process for the Preparation Thereof |
US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
IN188750B (en) | 1999-12-04 | 2002-11-02 | Khamar Bakulesh Dr Mafatlal | |
US6294553B1 (en) * | 2000-02-15 | 2001-09-25 | Allergan Sales, Inc. | Method for treating ocular pain |
US6444681B1 (en) | 2000-06-09 | 2002-09-03 | The Ohio State University Research Foundation | Methods and compositions for treating Raynaud's Phenomenon and scleroderma |
WO2002005853A2 (en) * | 2000-07-14 | 2002-01-24 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
AU2002360436A1 (en) | 2001-11-30 | 2003-06-17 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
IL147921A0 (en) * | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
US7345065B2 (en) * | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US20050020600A1 (en) | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
CA2567401C (en) | 2004-05-25 | 2013-11-12 | Sansrosa Pharmaceutical Development, Inc. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
-
2003
- 2003-06-25 US US10/607,439 patent/US20040266776A1/en not_active Abandoned
-
2004
- 2004-06-22 CA CA2530487A patent/CA2530487C/en not_active Expired - Fee Related
- 2004-06-22 KR KR1020057024881A patent/KR20060023575A/en not_active Application Discontinuation
- 2004-06-22 WO PCT/US2004/020194 patent/WO2005002580A1/en active Application Filing
- 2004-06-22 JP JP2006517594A patent/JP2007524625A/en active Pending
- 2004-06-22 EP EP04755981A patent/EP1638569B1/en not_active Expired - Lifetime
- 2004-06-22 CN CN2011104449533A patent/CN102579448A/en active Pending
- 2004-06-22 AT AT04755981T patent/ATE539751T1/en active
- 2004-06-22 MX MXPA05013900A patent/MXPA05013900A/en active IP Right Grant
- 2004-06-22 CN CNA2004800178422A patent/CN1812791A/en active Pending
- 2004-06-22 ES ES04755981T patent/ES2376878T3/en not_active Expired - Lifetime
- 2004-06-22 BR BRPI0411826-0A patent/BRPI0411826A/en not_active IP Right Cessation
- 2004-06-22 AU AU2004253500A patent/AU2004253500A1/en not_active Abandoned
- 2004-06-22 DK DK04755981.0T patent/DK1638569T3/en active
- 2004-06-25 TW TW093118660A patent/TWI371276B/en not_active IP Right Cessation
-
2006
- 2006-09-28 HK HK06110807.6A patent/HK1090282A1/en not_active IP Right Cessation
-
2008
- 2008-05-02 US US12/114,727 patent/US7977335B2/en not_active Expired - Lifetime
- 2008-05-02 US US12/114,719 patent/US20080207627A1/en not_active Abandoned
-
2010
- 2010-11-18 AU AU2010241513A patent/AU2010241513B9/en not_active Ceased
-
2011
- 2011-12-13 JP JP2011272494A patent/JP2012092123A/en active Pending
-
2012
- 2012-06-01 US US13/486,847 patent/US20120302574A1/en not_active Abandoned
- 2012-10-15 US US13/652,179 patent/US20130102612A1/en not_active Abandoned
-
2013
- 2013-02-15 US US13/768,901 patent/US20130217694A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2005002580A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005115395A2 (en) | 2004-05-25 | 2005-12-08 | Sansrosa Pharmaceutical Development, Inc. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
Also Published As
Publication number | Publication date |
---|---|
CA2530487C (en) | 2011-11-01 |
US20040266776A1 (en) | 2004-12-30 |
AU2010241513B2 (en) | 2011-09-22 |
EP1638569B1 (en) | 2012-01-04 |
JP2012092123A (en) | 2012-05-17 |
BRPI0411826A (en) | 2006-08-08 |
AU2004253500A1 (en) | 2005-01-13 |
US20130217694A1 (en) | 2013-08-22 |
ES2376878T3 (en) | 2012-03-20 |
US7977335B2 (en) | 2011-07-12 |
TW200524611A (en) | 2005-08-01 |
US20120302574A1 (en) | 2012-11-29 |
CN1812791A (en) | 2006-08-02 |
JP2007524625A (en) | 2007-08-30 |
US20080207628A1 (en) | 2008-08-28 |
CA2530487A1 (en) | 2005-01-13 |
DK1638569T3 (en) | 2012-04-02 |
MXPA05013900A (en) | 2006-02-24 |
TWI371276B (en) | 2012-09-01 |
ATE539751T1 (en) | 2012-01-15 |
US20080207627A1 (en) | 2008-08-28 |
CN102579448A (en) | 2012-07-18 |
WO2005002580A1 (en) | 2005-01-13 |
AU2010241513B9 (en) | 2011-10-20 |
KR20060023575A (en) | 2006-03-14 |
US20130102612A1 (en) | 2013-04-25 |
HK1090282A1 (en) | 2006-12-22 |
AU2010241513A1 (en) | 2010-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7977335B2 (en) | Methods of preventing and reducing the severity of stress-associated conditions | |
US20050059664A1 (en) | Novel methods for identifying improved, non-sedating alpha-2 agonists | |
JP5673973B2 (en) | Novel methods and compositions for alleviating pain | |
US4742054A (en) | Treatment of mammals suffering from damage to the central nervous system | |
KR100797603B1 (en) | Use of dopamine d2/d3 receptor agonists to treat fibromyalgia | |
JP2003530429A (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
JP2008505173A (en) | Methods and compositions for treating pain and other α2 adrenergic mediated conditions | |
EP2156833A1 (en) | Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient | |
JP2012131829A (en) | Use of mglur5 antagonist for treatment of pruritic condition | |
US4855325A (en) | Treatment of mammals suffering from damage to the central nervous system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051222 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1090282 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20080605 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 539751 Country of ref document: AT Kind code of ref document: T Effective date: 20120115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: NOVAGRAAF INTERNATIONAL SA |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602004035989 Country of ref document: DE Effective date: 20120301 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2376878 Country of ref document: ES Kind code of ref document: T3 Effective date: 20120320 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120404 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120405 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120504 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120104 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120104 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1090282 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 539751 Country of ref document: AT Kind code of ref document: T Effective date: 20120104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120104 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120104 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120104 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120104 |
|
26N | No opposition filed |
Effective date: 20121005 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120630 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120104 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602004035989 Country of ref document: DE Effective date: 20121005 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120622 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040622 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20140627 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20140627 Year of fee payment: 11 Ref country code: ES Payment date: 20140626 Year of fee payment: 11 Ref country code: IT Payment date: 20140624 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20140625 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20140626 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20140627 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20150630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150622 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150623 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20150701 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150622 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150630 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150701 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150630 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150630 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20160929 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150623 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230320 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230509 Year of fee payment: 20 Ref country code: DE Payment date: 20230509 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230510 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 602004035989 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20240621 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20240621 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20240621 |